Drugs / BI 1819479
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07065617 | Aug → Oct 2025 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT05467475 | Oct 2022 → Jan 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05469646 | Aug → Dec 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05440799 | Jul 2022 → Aug 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04801693 | May 2021 → Apr 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06335303 | Sep 2024 → Nov 2025 | idiopathic pulmonary fibrosis | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1819479 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05467475 ↗ |
| Action | Inhibit | “BI 1819479, an LPA pathway inhibitor” PMID 41846682 ↗ Mar 2026 |
| Route | Oral | “Following oral administration” NCT05467475 ↗ |